Timing of treatment for nonneutropenic patients colonized with Candida

American Journal of Surgery

Volumn 172, Issue 6 A, 1996, Pages 44s-48s

  Solomkin, Joseph S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE;

CANDIDIASIS; CONFERENCE PAPER; DOSE TIME EFFECT RELATION; DRUG MECHANISM; FUNGEMIA; FUNGUS CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0030464619     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00350-9     Document Type: Conference Paper

References (62)

1. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;91:72S-75S.
2. Jarvis WR, Edwards JR, Culver DH, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am J Med. 1991;91:185S-191S.
3. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis. 1993;167:1247-51.
4. Rose HD. Venous catheter-associated candidemia. Am J Med Sci. 1978;275:265-9.
5. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis. 1992;15:414-21.
6. Marsh PK, Tally FP, Kellum J, Callow A, Gorbach SL. Candida infections in surgical patients. Ann Surg. 1982;198:42-7.
7. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia. Its natural course and clinical significance. Am J Med. 1979;67:51-8.
8. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med. 1987;147:2117-20.
9. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis. 1989;11:379-90.
10. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642-5.
11. Edwards JE. Should all patients with candidemia be treated with antifungal agents? Clin Infect Dis. 1992;15:422-3.
12. Aloia T, Solomkin J, Fink AS, et al. Candida in pancreatic infection: a clinical experience. [Review]. Am Surg. 1994;60: 793-6.
13. Wilborn WH, Montes LF. Scanning electron microscopy of oral lesions in chronic mucocutaneous candidiasis. JAMA. 1980;244:2294-7.
14. Myerowitz RL. Gastrointestinal and disseminated candidiasis. An experimental model in the immunosuppressed rat. Arch Pathol Lab Med. 1981:105:138-43.
15. Odds FC, Evans EG. Distribution of pathogenic yeasts and humoral antibodies to Candida among hospital inpatients. J Clin Pathol. 1980;33:750-7.
16. 2-receptor antagonists. Digestion. 1983;28:158-63.
17. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med. 1989;149:2349-53.
18. Edwards JE, Filler SG. Current strategies for treating invasive candidiasis: emphasis on infections in nonneutropenic patients. Clin Infect Dis. 1992;14(suppl 1):S106-S113.
19. Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol. 1977;68:29-37.
20. Gaines JD, Remington JS. Disseminated candidiasis in the surgical patient. Surgery. 1972;72:730-6.
21. Parker JC, McCloskey JJ, Knauer KA. Pathobiologic features of human candidiasis. A common deep mycosis of the brain, heart and kidney in the altered host. Am J Clin Pathol. 1976;65:991-1000.
22. Parker JC. The potentially lethal problem of cardiac candidosis. Am J Clin Pathol. 1980;73:356-61.
23. Myerowitz RL. Ultrastructural observations in disseminated candidiasis. Arch Pathol Lab Med. 1978;102:506-11.
24. Sandovsky Losica H, Barr Nea L, Segal E. Fatal systemic candidiasis of gastrointestinal origin: an experimental model in mice compromised by anti-cancer treatment. J Med Vet Mycol. 1992;30:219-31.
25. Narayanan R, Joyce WA, Greenfield RA. Gastrointestinal candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun. 1991;59:2116-9.
26. Morgan DJ, Ching MS, Raymond K, et al. Elimination of amphotericin B in impaired renal function. Clin Pharmacol Ther. 1983;34:248-53.
27. Calderone RA, Braun PC. Adherence and receptor relationships of Candida albicans. Microbiol Rev. 1991;55:1-20.
28. Douglas LJ. Adhesion of Candida species to epithelial surfaces. Crit Rev Microbiol. 1987;15:27-43.
29. Rotrosen D, Calderone RA, Edwards JE. Adherence of Candida species to host tissues and plastic. Rev Infect Dis. 1986;8:73-85.
30. Edwards JE, Mayer CL, Filler SG, Wadsworth E, Calderone RA. Cell extracts of Candida albicans block adherence of the organisms to endothelial cells. Infect Immunol. 1992;60:3087-91.
31. Douglas LJ. Candida proteinases and candidosis. Crit Rev Biotechnol. 1988;8:121-9.
32. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-30.
33. Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med. 1995;155:2429-35.
34. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis. 1992;14:875-83.
35. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992;15:1003-18.
36. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 1994;330:263-71.
37. Joly V, Bolard J, Yeni P. In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother. 1992;36:1799-804.
38. Van den Bossche H, Willemsens G, Cools W, Marichal P, Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-substituted imidazoles and triazoles. Biochem Soc Trans. 1983;11:665-7.
39. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibitiing cytochrome P-450-dependent enzymes. J Clin Invest. 1983;71:1495-9.
40. Van den Bossche H, Bellens D, Cools W. Cytochrome P-450: target for itraconazole. Drug Dev Res. 1986;8:287-96.
41. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990;12:308-29.
42. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med. 1989;87:614-20.
43. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery. 1980;88:524-30.
44. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg. 1994;220:751-8.
45. Guiot HF, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis. 1994;18:525-32.
46. Karabinis A, Hill C, Leclercq B, Tancrede C, Baume D, Andremont A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol. 1988;26:429-32.
47. Rowen JL, Rench MA, Kozinetz CA, Adams JM Jr, Baker CJ. Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J Pediatr. 1994;124:789-94.
48. Alden SM, Frank E, Flancbaum L. Abdominal candidiasis in surgical patients. Am Surg. 1989;55:45-9.
49. Rutledge R, Mandel SR, Wild RE. Candida species. Insignificant contaminant or pathogenic species. Am Surg. 1986;52:299-302.
50. Fan Havard P, Capano D, Smith SM, Mangia A, Eng RH. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother. 1991;35:2302-5.
51. Wong Beringer A, Jacobs RA, Guglielmo BJ. Treatment of funguria. JAMA. 1992;267:2780-5.
52. Fisher JF, Chew WH, Shadomy S, Duma RJ, Mayhall CG, House WC. Urinary tract infections due to Candida albicans. Rev Infect Dis. 1982;4:1107-18.
53. Medoff G. Controversial areas in antifungal chemotherapy: short-course and combination therapy with amphotericin B. Rev Infect Dis. 1987;9:403-7.
54. Solomkin JS, Flohr A, Simmons RL. Candida infections in surgical patients. Dose requirements and toxicity of amphotericin B. Ann Surg. 1982;195:177-85.
55. Flannery MT, Simmons DB, Saba H, Altus P, Wallach PM, Adelman HM. Fluconazole in the treatment of hepatosplenic candidiasis. Arch Intern Med. 1992;152:406-8.
56. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med. 1991;151:2458-64.
57. Rantala A, Niinikoski J, Lehtonen OP. Yeasts in blood cultures: impact of early therapy. Scand J Infect Dis. 1989;21:557-61.
58. Soutter DI, Todd TR. Systemic candidiasis in a surgical intensive care unit. Can J Surg. 1986;29:197-9.
59. Solomkin JS, Flohr AM, Simmons RL. Indications for therapy for fungemia in postoperative patients. Arch Surg. 1982;117: 1272-5.
60. Edwards JE, Foos RY, Montgomery JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore). 1974;53:47-75.
61. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med. 1989;149:2226-8.
62. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158-63.